WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Table of Contents
Close this folderRegulatory decisions
View the documentAlbumin (human) B batches withdrawn: increase in aluminium level: Austria
View the documentAstemizole - warning concerning arrhythmias: Brazil
View the documentChlormezanone - withdrawn: Zimbabwe
View the documentChlorzoxazone - warning: hepatotoxicity: Chile
View the documentCidofovir - adverse reactions: nephrotoxicity, uveitis/iritis and hearing loss: Gilead Sciences, USA
View the documentFenfluramine and dexfenfluramine - temporary suspension: Brazil
View the documentFenfluramine and dexfenfluramine - warning concerning adverse reactions: Chile
View the documentIonic contrast media - notice of withdrawal: Germany
View the documentLaxatives containing aloe, bisacodyl, cascara sagrada and senna - proposed reclassification: USA
View the documentMeloxicam - data sheet revised: gastrointestinal and skin reactions: UK
View the documentMetamizole sodium - withdrawn due to agranulocytosis: Zimbabwe
View the documentMibefradil - suspended: Germany
View the documentNifedipine - re-approved in myocardial infarction: New Zealand
View the documentPsorial ointment - sales prohibited: undeclared cortisone ingredients: Sweden
View the documentPsorigon cream & lotion - withdrawn: undeclared cortisone ingredients: Germany, USA
View the documentTiclopidine - revised data sheet: thrombotic thrombocytopenic purpura: Roche, USA
View the documentTroglitazone - revised instructions for use: Parke-Davis, USA
View the documentVitamin A and betacarotene - labelling claim prohibited: USA
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
Open this folder and view contentsMedical devices
Open this folder and view contentsGeneral information
Open this folder and view contentsMedication errors
Open this folder and view contentsVeterinary medicine
 

Chlormezanone - withdrawn: Zimbabwe

Zimbabwe. The Medicines Control Authority has cancelled the registration of all chlormezanone-containing products in the light of international actions taken on the basis of a safety evaluation of chlormezanone. This drug has been associated with an unacceptable incidence of Stevens-Johnson syndrome.

[See also Pharmaceuticals Newsletters Nos. 3&4, March & April 1998, 1&2, January & February 1997, 11&12, November & December 1997 and DRS Alert No. 53, 18 October 1996]

Reference: Drug Information Bulletin Vol.2, No.1, March 1998.

to previous section to next section
 

Last updated: May 3, 2013